Takeda Pharmaceutical Files 6-K
Ticker: TKPHF · Form: 6-K · Filed: Jul 31, 2024 · CIK: 1395064
| Field | Detail |
|---|---|
| Company | Takeda Pharmaceutical Co Ltd (TKPHF) |
| Form Type | 6-K |
| Filed Date | Jul 31, 2024 |
| Risk Level | low |
| Pages | 16 |
| Reading Time | 19 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 6-K, foreign-private-issuer, regulatory-filing
TL;DR
Takeda filed a 6-K on 7/31/24, confirming its Tokyo HQ.
AI Summary
Takeda Pharmaceutical Company Limited filed a Form 6-K on July 31, 2024, reporting as a foreign private issuer. The filing indicates Takeda's principal executive offices are located at 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan.
Why It Matters
This filing serves as an update for investors regarding Takeda's status as a foreign private issuer, providing essential contact and location information.
Risk Assessment
Risk Level: low — This is a routine filing for a foreign private issuer and does not contain specific financial or operational disclosures that would indicate significant risk.
Key Players & Entities
- Takeda Pharmaceutical Company Limited (company) — Filer
- 0001395064-24-000153 (filing_id) — Accession Number
- 20240731 (date) — Filing Date
- 001-38757 (company_id) — Commission File Number
FAQ
What type of filing is this?
This is a Form 6-K, a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
Who is the filer?
The filer is Takeda Pharmaceutical Company Limited.
When was this filing made?
The filing was made on July 31, 2024.
Where are Takeda's principal executive offices located?
Takeda's principal executive offices are located at 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan.
Does Takeda file annual reports under Form 20-F or 40-F?
Takeda indicates it files annual reports under Form 20-F.
Filing Stats: 4,675 words · 19 min read · ~16 pages · Grade level 6.5 · Accepted 2024-07-31 06:02:04
Filing Documents
- form6k_073124.htm (6-K) — 786KB
- exhibit991_073124.htm (EX-99.1) — 559KB
- imagea.jpg (GRAPHIC) — 8KB
- 0001395064-24-000153.txt ( ) — 1357KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. TAKEDA PHARMACEUTICAL COMPANY LIMITED Date July 31, 2024 By s Norimasa Takeda Norimasa Takeda Chief Accounting Officer and Corporate Controller Earnings Report ( Kessan Tanshin ) for the Three-month Period Ended June 30, 2024 (IFRS, Consolidated) July 31, 2024 Takeda Pharmaceutical Company Limited Stock exchange listings Tokyo, Nagoya, Fukuoka, Sapporo TSE Code 4502 URL httpswww.takeda.com Representative Christophe Weber, President CEO Contact Christopher O'Reilly Telephone +81-3-3278-2306 Email takeda.ir.contacttakeda.com Global Head of IR, Global Finance Scheduled date of dividend payment commencement - Supplementary materials for the financial statements Yes Presentation to explain the financial statements Yes (Million JPY, rounded to the nearest million) 1. Consolidated Financial Results for the Three-month Period Ended June 30, 2024 (April 1 to June 30, 2024 ) (1) Consolidated Operating Results (year to date) (Percentage figures represent changes over the same period of the previous year) Revenue Operating profit Profit before tax Net profit for the period (Million JPY) (%) (Million JPY) (%) (Million JPY) (%) (Million JPY) (%) Three-month Period Ended June 30, 2024 1,207,990 14.1 166,329 (1.3) 136,604 1.2 95,299 6.6 Three-month Period Ended June 30, 2023 1,058,618 8.9 168,571 12.0 135,033 (13.1) 89,406 (14.9) Net profit attributable to income for the period Basic earnings per share Diluted earnings per share (Million JPY) (%) (Million JPY) (%) (JPY) (JPY) Three-month Period Ended June 30, 2024 95,248 6.5 660,122 (4.9) 60.71 59.94 Three-month Period Ended June 30, 2023 89,395 (14.9) 693,874 (11.6) 57.51 57.12 Core Operating Profit Core EPS (Billion JPY) (%) (JPY) Three-month Period E